Lates News

Every AI newsletter, open-source securities released a research report on March 18, giving Senxuan Medicine (920946.SH) a "buy" rating. The rating reasons mainly include: 1) 2025 performance report: revenue of 553 million yuan, +3% year-on-year, net profit attributable to parent of 132 million yuan, +6% year-on-year; 2) The domestic sales price of products has slightly decreased, actively promoting the overseas registration of new and old products, and overseas sales support performance growth; 3) Expanding into fields such as engineering plastics, fibers, and medicine, planning to expand into new scenarios such as clean fuel and dental materials. (Daily Economic News)